Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PRAX NASDAQ:SLRN NASDAQ:SYRE NASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePRAXPraxis Precision Medicines$54.48+4.0%$47.83$26.70▼$91.83$1.15B2.61450,300 shs289,046 shsSLRNAcelyrin$2.27$2.27$1.85▼$7.10$229.17M1.071.29 million shsN/ASYRESpyre Therapeutics$16.16-1.2%$16.40$10.91▼$40.26$977.57M2.87609,675 shs260,864 shsUPBUpstream Bio$18.78+8.3%$16.73$5.14▼$29.46$1.01BN/A382,363 shs553,631 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePRAXPraxis Precision Medicines-0.11%+8.38%+15.02%+21.33%-9.42%SLRNAcelyrin0.00%0.00%0.00%0.00%-53.96%SYRESpyre Therapeutics+0.74%+7.00%-0.79%+5.62%-42.58%UPBUpstream Bio+0.46%+4.14%+1.23%+60.70%+1,733,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePRAXPraxis Precision Medicines$54.48+4.0%$47.83$26.70▼$91.83$1.15B2.61450,300 shs289,046 shsSLRNAcelyrin$2.27$2.27$1.85▼$7.10$229.17M1.071.29 million shsN/ASYRESpyre Therapeutics$16.16-1.2%$16.40$10.91▼$40.26$977.57M2.87609,675 shs260,864 shsUPBUpstream Bio$18.78+8.3%$16.73$5.14▼$29.46$1.01BN/A382,363 shs553,631 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePRAXPraxis Precision Medicines-0.11%+8.38%+15.02%+21.33%-9.42%SLRNAcelyrin0.00%0.00%0.00%0.00%-53.96%SYRESpyre Therapeutics+0.74%+7.00%-0.79%+5.62%-42.58%UPBUpstream Bio+0.46%+4.14%+1.23%+60.70%+1,733,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePRAXPraxis Precision Medicines 2.91Moderate Buy$85.5657.05% UpsideSLRNAcelyrin 2.33Hold$7.33223.05% UpsideSYRESpyre Therapeutics 3.22Buy$54.29235.86% UpsideUPBUpstream Bio 3.00Buy$56.50200.85% UpsideCurrent Analyst Ratings BreakdownLatest SLRN, SYRE, PRAX, and UPB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/26/2025SYRESpyre TherapeuticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$43.009/18/2025PRAXPraxis Precision MedicinesJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$83.009/16/2025SYRESpyre TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.009/3/2025PRAXPraxis Precision MedicinesLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/2/2025PRAXPraxis Precision MedicinesJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/6/2025SYRESpyre TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$65.008/5/2025PRAXPraxis Precision MedicinesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$105.00 ➝ $115.007/29/2025PRAXPraxis Precision MedicinesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.007/18/2025PRAXPraxis Precision MedicinesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$105.007/8/2025PRAXPraxis Precision MedicinesOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$97.00 ➝ $115.00(Data available from 9/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPRAXPraxis Precision Medicines$8.55M134.12N/AN/A$23.90 per share2.28SLRNAcelyrinN/AN/AN/AN/A$6.74 per shareN/ASYRESpyre Therapeutics$890K1,096.90N/AN/A$7.04 per share2.30UPBUpstream Bio$2.72M371.80N/AN/A$8.77 per share2.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePRAXPraxis Precision Medicines-$182.82M-$12.29N/AN/AN/A-2,137.48%-60.07%-54.84%11/5/2025 (Estimated)SLRNAcelyrin-$381.64M-$2.69N/AN/AN/AN/A-44.12%-39.02%N/ASYRESpyre Therapeutics-$208.02M-$3.40N/AN/AN/AN/A-71.30%-38.69%11/6/2025 (Estimated)UPBUpstream Bio-$62.81MN/A0.00N/AN/A-3,836.58%-35.90%-26.26%11/6/2025 (Estimated)Latest SLRN, SYRE, PRAX, and UPB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025UPBUpstream Bio-$0.61-$0.74-$0.13-$0.74$0.32 million$0.94 million8/5/2025Q2 2025SYRESpyre Therapeutics-$0.73-$0.49+$0.24-$0.49N/AN/A8/4/2025Q2 2025 & Study ResultPRAXPraxis Precision Medicines-$3.40-$3.31+$0.09-$3.31$0.15 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ASLRNAcelyrinN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPRAXPraxis Precision MedicinesN/A6.316.31SLRNAcelyrinN/A7.157.15SYRESpyre TherapeuticsN/A6.496.49UPBUpstream BioN/A38.2738.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPRAXPraxis Precision Medicines67.84%SLRNAcelyrin87.31%SYRESpyre Therapeutics80.39%UPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipPRAXPraxis Precision Medicines2.70%SLRNAcelyrin13.60%SYRESpyre Therapeutics6.20%UPBUpstream Bio13.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePRAXPraxis Precision Medicines11021.05 million20.48 millionOptionableSLRNAcelyrin135100.95 million86.68 millionOptionableSYRESpyre Therapeutics7360.40 million56.66 millionOptionableUPBUpstream Bio3853.91 million46.60 millionN/ASLRN, SYRE, PRAX, and UPB HeadlinesRecent News About These CompaniesUpstream Bio’s verekitug shows prevention of TSLP binding in respiratory disease2 hours ago | msn.comUpstream Bio (NASDAQ:UPB) Trading 4.2% Higher - Still a Buy?3 hours ago | marketbeat.comUpstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European ...September 30 at 8:09 AM | finance.yahoo.comUpstream Bio, Inc. Presents Data on Verekitug's Mechanism of Action at ERS Congress, Highlighting Its Potential in Treating TSLP-Driven Severe Respiratory DiseasesSeptember 30 at 4:31 AM | quiverquant.comQUpstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society CongressSeptember 30 at 4:15 AM | globenewswire.comUpstream Bio (NASDAQ:UPB) Shares Down 5.3% - Here's What HappenedSeptember 18, 2025 | marketbeat.comUpstream Bio (NASDAQ:UPB) Trading 5.9% Higher - Still a Buy?September 17, 2025 | marketbeat.comUpstream Bio, Inc. (UPB): A Bull Case TheorySeptember 16, 2025 | msn.comTD Cowen Remains a Buy on Upstream Bio, Inc. (UPB)September 10, 2025 | theglobeandmail.comUpstream Bio Announces Positive Phase 2 Trial ResultsSeptember 9, 2025 | theglobeandmail.comUpstream Bio, Inc. CEO Rand Sutherland to Speak at Stifel 2025 Virtual Immunology and Inflammation ForumSeptember 9, 2025 | quiverquant.comQUpstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation ForumSeptember 9, 2025 | globenewswire.comParkman Healthcare Partners LLC Invests $1.43 Million in Upstream Bio, Inc. $UPBSeptember 8, 2025 | marketbeat.com22,586 Shares in Upstream Bio, Inc. $UPB Bought by Nuveen LLCSeptember 8, 2025 | marketbeat.comUpstream Bio, Inc. - Special CallSeptember 7, 2025 | seekingalpha.comUpstream Bio, Inc. (UPB) Special Call - SlideshowSeptember 5, 2025 | seekingalpha.comADAR1 Capital Management LLC Makes New $92,000 Investment in Upstream Bio, Inc. $UPBSeptember 5, 2025 | marketbeat.comUpstream Bio (NASDAQ:UPB) Sees Large Volume Increase - Time to Buy?September 4, 2025 | marketbeat.comUpstream Bio Shares Rise on Positive Data for Sinus-Disease TreatmentSeptember 3, 2025 | marketwatch.comPositive Buy Rating for Upstream Bio, Inc. Driven by Promising Clinical Trial Results for VerekitugSeptember 2, 2025 | tipranks.comChasing pharma heavyweights, Upstream posts phase 2 sinusitis win but stock flows downhillSeptember 2, 2025 | fiercebiotech.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLRN, SYRE, PRAX, and UPB Company DescriptionsPraxis Precision Medicines NASDAQ:PRAX$54.48 +2.10 (+4.00%) As of 03:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Acelyrin NASDAQ:SLRNAcelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.Spyre Therapeutics NASDAQ:SYRE$16.16 -0.20 (-1.20%) As of 03:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.Upstream Bio NASDAQ:UPB$18.78 +1.44 (+8.30%) As of 03:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AppLovin Stock Momentum Builds With $800+ Analyst Price Target Apple Stock Positioned for Holiday Gains With iPhone 17 Boost 3 Top-Rated Dividend Growth Stocks to Buy in October Top Insider Buys and Sells From September: Buy, Sell, or Hold? This ETF Weeds Out Small-Cap Underperformers Chewy Stock: Why Analysts Say Boring May Be the Best Buy Dividend ETF SCHD Draws Buyers as Fed Cuts Spark Rotation Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
